Evaluation of Neutrophil to Lymphocyte Ratio in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With a Combination of Cetuximab and Nivolumab in a Phase II Clinical Trial.

Am J Clin Oncol · 2026 · PMC13011960 · PMID 40905435

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a nonsignificant trendno p-value reported

Notably, while there was a significantly higher proportion of ≥2-year long-term survivors with low OT-NLR (9/20) compared with high OT-NLR (0/22) in the second-line+ cohort, the first-line cohort showed only a nonsignificant trend with low OT-NLR (11/21) compared with high OT-NLR (4/19).

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.